Neurotrope (NTRP) Issueds New 12-Month Low at $4.74

Neurotrope (NTRP) Issueds New 12-Month Low at $4.74

Shares of Neurotrope Inc (NASDAQ:NTRP) reached a new 52-week low during trading on Thursday . The company traded as low as $4.74 and last traded at $5.48, with a volume of 100 shares traded. The stock had previously closed at $5.66.

A number of analysts recently commented on NTRP shares. Maxim Group reiterated a “buy” rating and set a $16.00 price objective on shares of Neurotrope in a research report on Monday, August 13th. Zacks Investment Research raised Neurotrope from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Friday, August 17th.

Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings results on Tuesday, October 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05.

Large investors have recently modified their holdings of the business. Pathstone Family Office LLC acquired a new stake in Neurotrope in the 3rd quarter worth about $270,000. Renaissance Technologies LLC acquired a new stake in Neurotrope in the 2nd quarter worth about $281,000. Ingalls & Snyder LLC acquired a new stake in Neurotrope in the 2nd quarter worth about $326,000. Tanaka Capital Management Inc. boosted its stake in Neurotrope by 12.1% in the 2nd quarter. Tanaka Capital Management Inc. now owns 198,195 shares of the company’s stock worth $1,919,000 after buying an additional 21,455 shares during the last quarter. Finally, Cannell Peter B & Co. Inc. boosted its stake in Neurotrope by 3.7% in the 3rd quarter. Cannell Peter B & Co. Inc. now owns 280,793 shares of the company’s stock worth $2,474,000 after buying an additional 10,000 shares during the last quarter. 18.17% of the stock is currently owned by hedge funds and other institutional investors.

Neurotrope Company Profile (NASDAQ:NTRP)

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Featured Story: What is the float in trading stocks?

Related posts

Leave a Comment